95 related articles for article (PubMed ID: 9168922)
21. The role of Wilms' tumor genes.
Hirose M
J Med Invest; 1999 Aug; 46(3-4):130-40. PubMed ID: 10687307
[TBL] [Abstract][Full Text] [Related]
22. Reconstitution of the KRAB-KAP-1 repressor complex: a model system for defining the molecular anatomy of RING-B box-coiled-coil domain-mediated protein-protein interactions.
Peng H; Begg GE; Schultz DC; Friedman JR; Jensen DE; Speicher DW; Rauscher FJ
J Mol Biol; 2000 Feb; 295(5):1139-62. PubMed ID: 10653693
[TBL] [Abstract][Full Text] [Related]
23. A zinc finger truncation of murine WT1 results in the characteristic urogenital abnormalities of Denys-Drash syndrome.
Patek CE; Little MH; Fleming S; Miles C; Charlieu JP; Clarke AR; Miyagawa K; Christie S; Doig J; Harrison DJ; Porteous DJ; Brookes AJ; Hooper ML; Hastie ND
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):2931-6. PubMed ID: 10077614
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the DNA binding characteristics of the related zinc finger proteins WT1 and EGR1.
Hamilton TB; Borel F; Romaniuk PJ
Biochemistry; 1998 Feb; 37(7):2051-8. PubMed ID: 9485332
[TBL] [Abstract][Full Text] [Related]
25. Mutations in the interferon-sensitivity determining region of hepatitis C virus and transcriptional activity of the nonstructural region 5A protein.
Fukuma T; Enomoto N; Marumo F; Sato C
Hepatology; 1998 Oct; 28(4):1147-53. PubMed ID: 9755255
[TBL] [Abstract][Full Text] [Related]
26. Ornithine decarboxylase is a transcriptional target of tumor suppressor WT1.
Li RS; Law GL; Seifert RA; Romaniuk PJ; Morris DR
Exp Cell Res; 1999 Feb; 247(1):257-66. PubMed ID: 10047468
[TBL] [Abstract][Full Text] [Related]
27. Activation of the wt1 Wilms' tumor suppressor gene by NF-kappaB.
Dehbi M; Hiscott J; Pelletier J
Oncogene; 1998 Apr; 16(16):2033-9. PubMed ID: 9572484
[TBL] [Abstract][Full Text] [Related]
28. Differential regulation of the human Wilms tumour suppressor gene (WT1) promoter by two isoforms of PAX2.
McConnell MJ; Cunliffe HE; Chua LJ; Ward TA; Eccles MR
Oncogene; 1997 Jun; 14(22):2689-700. PubMed ID: 9178767
[TBL] [Abstract][Full Text] [Related]
29. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
30. Molecular heterogeneity and function of EWS-WT1 fusion transcripts in desmoplastic small round cell tumors.
Liu J; Nau MM; Yeh JC; Allegra CJ; Chu E; Wright JJ
Clin Cancer Res; 2000 Sep; 6(9):3522-9. PubMed ID: 10999739
[TBL] [Abstract][Full Text] [Related]
31. A novel WT1 gene mutation in a newborn infant diagnosed with Denys-Drash syndrome.
Hakan N; Aydin M; Erdogan O; Cavusoglu YH; Aycan Z; Ozaltin F; Zenciroglu A; Apaydin S; Gunes R; Sahin G; Cinar G; Okumus N
Genet Couns; 2012; 23(2):255-61. PubMed ID: 22876585
[TBL] [Abstract][Full Text] [Related]
32. A WT1 exon 1 mutation in a child diagnosed with Denys-Drash syndrome.
Little S; Hanks S; King-Underwood L; Picton S; Cullinane C; Rapley E; Rahman N; Pritchard-Jones K
Pediatr Nephrol; 2005 Jan; 20(1):81-5. PubMed ID: 15503171
[TBL] [Abstract][Full Text] [Related]
33. Transcriptional activity of testis-determining factor SRY is modulated by the Wilms' tumor 1 gene product, WT1.
Matsuzawa-Watanabe Y; Inoue J; Semba K
Oncogene; 2003 Sep; 22(39):7900-4. PubMed ID: 12970737
[TBL] [Abstract][Full Text] [Related]
34. Cooperative interaction of ets-1 with USF-1 required for HIV-1 enhancer activity in T cells.
Sieweke MH; Tekotte H; Jarosch U; Graf T
EMBO J; 1998 Mar; 17(6):1728-39. PubMed ID: 9501094
[TBL] [Abstract][Full Text] [Related]
35. Novel WT1 exon 9 mutation (D396Y) in a patient with early onset Denys Drash syndrome.
Little M; Carman G; Donaldson E
Hum Mutat; 2000 Apr; 15(4):389. PubMed ID: 10738002
[No Abstract] [Full Text] [Related]
36. WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.
Yang Y; Jeanpierre C; Dressler GR; Lacoste M; Niaudet P; Gubler MC
Am J Pathol; 1999 Jan; 154(1):181-92. PubMed ID: 9916932
[TBL] [Abstract][Full Text] [Related]
37. The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells.
Han Y; San-Marina S; Yang L; Khoury H; Minden MD
Breast Cancer Res; 2007; 9(4):R43. PubMed ID: 17634147
[TBL] [Abstract][Full Text] [Related]
38. Wilms' tumor suppressor gene WT1: from structure to renal pathophysiologic features.
Mrowka C; Schedl A
J Am Soc Nephrol; 2000 Nov; 11 Suppl 16():S106-15. PubMed ID: 11065340
[TBL] [Abstract][Full Text] [Related]
39. Proto-oncogene N-myc promoter is down regulated by the Wilms' tumor suppressor gene WT1.
Zhang X; Xing G; Saunders GF
Anticancer Res; 1999; 19(3A):1641-8. PubMed ID: 10470095
[TBL] [Abstract][Full Text] [Related]
40. Role for first zinc finger of WT1 in DNA sequence specificity: Denys-Drash syndrome-associated WT1 mutant in ZF1 enhances affinity for a subset of WT1 binding sites.
Wang D; Horton JR; Zheng Y; Blumenthal RM; Zhang X; Cheng X
Nucleic Acids Res; 2018 May; 46(8):3864-3877. PubMed ID: 29294058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
